Subcutaneous trastuzumab deruxtecan plus hyaluronidase for metastatic solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 study uses a dose-escalation and dose-expansion design to find safe and tolerable subcutaneous doses of trastuzumab deruxtecan (T-DXd) administered with hyaluronidase and to collect pharmacokinetic and preliminary efficacy data. Participants are adults with recurrent or metastatic solid tumors, with HER2 testing required for populations where that status determines eligibility. The study will escalate doses to define a recommended subcutaneous dose and then expand cohorts to further characterize safety and activity. Treatments are given at selected U.S. research sites and participants are followed for safety, drug levels, and tumor response.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Adults ≥18 years or the minimum legal adult age (whichever is greater).
2. a) Disease State: If HER2 status is required for eligibility (for all populations), a documented HER2 test result must be available.

   Breast Cancer: adults with pathologically documented unresectable or metastatic breast cancer HER2-positive BC: have received a prior anti-HER2-based regimen. For HER2-positive BC participants in Part 2 only, prior anti-HER2 based therapy should have been received in either:
   * the metastatic setting, or
   * the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. HR-, HER2-low BC: have received a prior systemic cytotoxic therapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing (neo)adjuvant chemotherapy. HR+, HER2-low/ultralow BC: have received previous ET AND an additional line of ET must not be the next line of treatment considered in the participant's best interest.
   * For participants in Part 2 with HR+ HER-2low/ultralow BC, the following criteria also apply:
   * had disease progression while receiving 1 previous line of ET with a CDK4/6i and is not expected to benefit from immediate use of a second line of ET, OR
   * had disease progression on at least 2 previous lines of ET with or without a target therapy such as CDK4/6, mTOR or PI3-K inhibitors) administered for the treatment of metastatic disease
   * participants may not have received more than 2 prior lines of cytotoxic therapy in the recurrent or metastatic setting. NSCLC, HER2 mut: adults with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy.

     b) Part 2 only: At least 1 RECIST 1.1 measurable lesion on CT or MRI.
3. Radiologic or objective evidence of disease progression on or after the last systemic therapy prior to starting trial intervention.

Key Exclusion Criteria:

1\. Prior treatment with ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor; 4. Medical history of MI within 6 months before enrollment or symptomatic CHF (New York Heart Association class II to IV). Participants with troponin levels above ULN at screening (as defined by the manufacturer), and without any MI-related symptoms should have a cardiologic consultation during the Screening Period to rule out MI.

5\. Has a corrected QT interval (QTcF) prolongation to \> 480 ms (regardless of participant's sex) based on average of the screening triplicate 12-lead ECG. 6. Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.

Where it's running

• Research Site
  Newport Beach, California, United States Recruiting
• Research Site
  Atlanta, Georgia, United States Recruiting
• Research Site
  Las Vegas, Nevada, United States Recruiting
• Research Site
  Charlotte, North Carolina, United States Recruiting
• Research Site
  Maumee, Ohio, United States Recruiting
• Research Site
  Nashville, Tennessee, United States Recruiting

Study contacts

• Study coordinator: Contact for Trial Information
• Email: CTRinfo_us@daiichisankyo.com
• Phone: 908-992-6400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating Ifinatamab Deruxtecan for Recurrent or Metastatic Solid Tumors

  This study is testing a new drug called ifinatamab deruxtecan to see if it can help people with recurrent or metastatic solid tumors that have already been treated.

  Recruiting at 104 sites Phase 1/2 Daiichi Sankyo · Los Angeles, California and 119 other locations · NCT06330064

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• DS-3939a in solid tumors and non-small cell lung cancer

  This study tests DS-3939a, alone or with other anticancer drugs, in adults with solid tumors including locally advanced or metastatic NSCLC to see if it is safe and helps control the disease.

  Recruiting at 3 sites Phase 1/2 Daiichi Sankyo · Fayetteville, Arkansas and 75 other locations · NCT07739966

• HER3-DXd and T-DXd combo therapy in HR-positive, HER2-low/ultralow breast cancer

  This trial tests a combination of patritumab deruxtecan and trastuzumab deruxtecan in people with HR-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer to see if it is safe and shows anti-tumor activity.

  Recruiting at 7 sites Phase 1/2 Daiichi Sankyo · Los Angeles, California and 71 other locations · NCT07701941

• T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer

  This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.

  Recruiting at 5 sites Phase 3 Daiichi Sankyo · Columbia, Maryland and 4 other locations · NCT07683754

• DS1025a: first-in-human test in advanced solid tumors

  This first-in-human trial tests DS1025a in adults with advanced, metastatic, or unresectable solid tumors to see if it is safe and tolerable and to look for early signs of activity.

  Recruiting at 3 sites Phase 1 Daiichi Sankyo · Kashiwa and 2 other locations · NCT07681882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.